6620 Stock Overview
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Handa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$143.50 |
| 52 Week High | NT$206.00 |
| 52 Week Low | NT$132.50 |
| Beta | 1.37 |
| 1 Month Change | -12.50% |
| 3 Month Change | -17.77% |
| 1 Year Change | -12.50% |
| 3 Year Change | 396.54% |
| 5 Year Change | 306.52% |
| Change since IPO | 52.66% |
Recent News & Updates
Shareholder Returns
| 6620 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -15.3% | -1.0% | -3.7% |
| 1Y | -12.5% | 10.0% | 24.4% |
Return vs Industry: 6620 underperformed the TW Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: 6620 underperformed the TW Market which returned 24.4% over the past year.
Price Volatility
| 6620 volatility | |
|---|---|
| 6620 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6620's share price has been volatile over the past 3 months.
Volatility Over Time: 6620's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Toshiyo Chen | www.handapharma.com.tw |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products.
Handa Pharmaceuticals, Inc. Fundamentals Summary
| 6620 fundamental statistics | |
|---|---|
| Market cap | NT$20.25b |
| Earnings (TTM) | NT$726.89m |
| Revenue (TTM) | NT$1.11b |
27.9x
P/E Ratio18.3x
P/S RatioIs 6620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6620 income statement (TTM) | |
|---|---|
| Revenue | NT$1.11b |
| Cost of Revenue | NT$1.30m |
| Gross Profit | NT$1.11b |
| Other Expenses | NT$378.13m |
| Earnings | NT$726.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.15 |
| Gross Margin | 99.88% |
| Net Profit Margin | 65.70% |
| Debt/Equity Ratio | 0% |
How did 6620 perform over the long term?
See historical performance and comparison